Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Item
http://www.wikidata.org/entity/Q37119029
Anti-transferrin receptor-modified amphotericin B-loaded PLA-PEG nanoparticles cure Candidal meningitis and reduce drug toxicityRodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.Characterization and comparison of galactomannan enzyme immunoassay and quantitative real-time PCR assay for detection of Aspergillus fumigatus in bronchoalveolar lavage fluid from experimental invasive pulmonary aspergillosis.Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis.Emerging azole antifungals.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Rapid detection of triazole antifungal resistance in Aspergillus fumigatus.New generation azole antifungals in clinical investigation.Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations.Prognostic value of galactomannan: current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis.Animal Models for Studying Triazole Resistance in Aspergillus fumigatus.Endpoint Assessment in Rabbit Models of Invasive Pulmonary Aspergillosis and Mucormycosis.In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.Newer antifungal agents.Compartmental pharmacokinetics and tissue distribution of the antifungal triazole ravuconazole following intravenous administration of its di-lysine phosphoester prodrug (BMS-379224) in rabbits.
P2860

Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits.

Item
http://www.wikidata.org/entity/Q37119029
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy, safety, and plasma p ...... sistently neutropenic rabbits.
@en
Efficacy, safety, and plasma p ...... sistently neutropenic rabbits.
@nl
type
label
Efficacy, safety, and plasma p ...... sistently neutropenic rabbits.
@en
Efficacy, safety, and plasma p ...... sistently neutropenic rabbits.
@nl
prefLabel
Efficacy, safety, and plasma p ...... sistently neutropenic rabbits.
@en
Efficacy, safety, and plasma p ...... sistently neutropenic rabbits.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P577
P698
P921
P932
P356
P1433
P1476
Efficacy, safety, and plasma p ...... sistently neutropenic rabbits.
@en
P2093
P2860
P304
P31
P356
10.1128/AAC.48.4.1188-1196.2004
P407
P433
P478
P577
P698
P921
P932